Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18285369 | 0.92 | PDE4B (0.38) | CNR2CNR1ANO1PDE4BPDE4A | |
| SCHEMBL18285299 | 0.90 | CNR1 (0.43) | CNR1ANO1PDE4BPDE4APDE4C | |
| SCHEMBL18285363 | 0.87 | PDE4B (0.35) | CNR2CNR1ANO1PDE4BPDE4A | |
| SCHEMBL18293056 | 0.86 | GRM5 (0.35) | CNR1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL18285317 | 0.86 | CNR2 (0.46) | CNR2CNR1GABRA5ANO1NPC1 | |
| SCHEMBL18285358 | 0.86 | P2RX3 (0.35) | CNR1ANO1PDE4BPDE4APDE4C | |
| SCHEMBL18706493 | 0.85 | CNR2 (0.42) | CNR2CNR1GABRA5ANO1NPC1 | |
| SCHEMBL18285302 | 0.84 | CNR1 (0.32) | CNR2CNR1ANO1PDE4BPDE4A | |
| SCHEMBL18389352 | 0.83 | CNR2 (0.41) | CNR2CNR1GABRA5ANO1NPC1 | |
| SCHEMBL18285320 | 0.83 | CNR2 (0.41) | CNR2CNR1GABRA5ANO1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3303299-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-24 | — | — | EP | claimed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | claimed |
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3303299-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | DRD3, GABRR3, DRD4 | CNR2 590/4885CNR1 214/4885GABRA5 63/4885 |
| US-10029989-B2 | Imidazole derivatives | DRD3, GABRR3, DRD4 | CNR2 590/4885CNR1 214/4885GABRA5 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.